Apnimed's Sulthiame Shows Promising Phase 2 Results for Treating Obstructive Sleep Apnea Apnimed's Phase 2 trial of Sulthiame published in The Lancet shows significant efficacy in treating obstructive sleep apnea, with promising safety data.

Apnimed's Sulthiame Shows Promising Phase 2 Results for Treating Obstructive Sleep Apnea #United_States #Cambridge #Obstructive_Sleep_Apnea #Apnimed #Sulthiame

Apnimed to Showcase Phase 3 Data for Groundbreaking Sleep Apnea Treatment at CHEST 2025 Apnimed will present new Phase 3 data for AD109, an innovative oral medication for obstructive sleep apnea, at the CHEST 2025 meeting in Chicago.

Apnimed to Showcase Phase 3 Data for Groundbreaking Sleep Apnea Treatment at CHEST 2025 #United_States #Chicago #Obstructive_Sleep_Apnea #Apnimed #AD109

Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025 At the World Sleep Congress 2025, Apnimed will present its groundbreaking oral therapy, AD109, aimed at alleviating obstructive sleep apnea.

Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025 #United_States #Cambridge #Obstructive_Sleep_Apnea #Apnimed #AD109

Vivos Highlights Undiagnosed Symptoms of Obstructive Sleep Apnea and Their Effects Vivos Therapeutics sheds light on neglected symptoms of Obstructive Sleep Apnea (OSA), urging clinicians to recognize life-altering signs for early intervention.

Vivos Highlights Undiagnosed Symptoms of Obstructive Sleep Apnea and Their Effects #USA #Littleton #Obstructive_Sleep_Apnea #Vivos_Therapeutics #OSA_Symptoms

New Study Links Obstructive Sleep Apnea to Women's Cognitive Decline and Dementia Risks A recent study reveals a troubling connection between obstructive sleep apnea and increased dementia risk, especially in women. Explore the implications and innovative treatments available.

New Study Links Obstructive Sleep Apnea to Women's Cognitive Decline and Dementia Risks #USA #Littleton #Obstructive_Sleep_Apnea #cognitive_health #Vivos_Therapeutics

Apnimed to Showcase Innovative Findings on Obstructive Sleep Apnea at SLEEP 2025 Annual Meeting At the upcoming SLEEP 2025 annual meeting, Apnimed will unveil key presentations highlighting the burden of obstructive sleep apnea, promising newer treatment avenues.

Apnimed to Showcase Innovative Findings on Obstructive Sleep Apnea at SLEEP 2025 Annual Meeting #United_States #Seattle #Obstructive_Sleep_Apnea #Apnimed #SLEEP_2025

FDA Grants Approval for Zepbound to Treat Obstructive Sleep Apnea in Obese Adults The FDA has approved Zepbound for treating obstructive sleep apnea in adults with obesity, marking a significant breakthrough in sleep medicine.

FDA Grants Approval for Zepbound to Treat Obstructive Sleep Apnea in Obese Adults #USA #FDA_Approval #Silver_Spring #Zepbound #Obstructive_Sleep_Apnea